Retrophin, a biopharmaceutical company, has a focus on developing and providing innovative treatments for individuals with rare diseases. Its primary product candidate in late-stage development is sparsentan, which has the potential to treat focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare disorders of the kidney that often lead to end-stage kidney disease. Retrophin is also conducting research in other rare diseases in conjunction with patient advocacy groups and government research entities, including NGLY1 deficiency and Alagille syndrome. Retrophin’s commercial products, Chenodal, Cholbam, Thiola, and Thiola EC, provide the necessary revenue to support their research and development efforts.
Retrophin, Inc.'s ticker is RTRX
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 201-500 employees working at Retrophin, Inc.
It is http://www.retrophin.com/index.php
Retrophin, Inc. is in the Healthcare sector
Retrophin, Inc. is in the Biotechnology industry
The following five companies are Retrophin, Inc.'s industry peers: